All News
Febuxostat Gets Reprieve from FDA Advisory Panel
On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol
Read Article
Only One-Third of Gout Patients Receive Urate-Lowering Drugs
The most recent analysis of National Health and Nutrition Examination Survey [NHANES] 2007-2016) data shows the prevalence of gout to be 9.3 million in the USA.
Read Article
RheumNow Podcast – Gout Spot Light (1.11.19)
Dr. Jack Cush discusses the highlights from the past week on RheumNow.com:
Read Article
RheumNow Podcast – A Grand New Year (1.4.19)
Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from RheumNow.com.
Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.
Sleep Apnea Increases Gout Risk
Both Gout and obstructive sleep apnea (OSA) comingle with a wide range of serious comorbidities. A matched retrospective cohort study from the UK Clinical Practice Research database shows those with OSA are at a higher risk of developing gout.
Read Article
Chronic Kidney Disease Increasing in the U.S.A.
JAMA has published the Global Burden of Disease (GBD) study showing that that, from 2002 to 2016, the US burden of chronic kidney disease (CKD) increased, with some states exhibiting more than twice the burden as others.
Read Article
Hepatic Safety of Urate Lowering Therapies in Gout
Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal)
Read Article
Treat-to-Target Strategy Cuts Mortality in Gout Patients
More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.
Read Article
RheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
Read Article
TRIPLE Trial Results
Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect.
Read Article
Gout and the Social Determinants of Health
During a fascinating gout session on October 21, Hyon Choi presented an important paper (abstract 874) which used data from the Health Professionals Follow-up Study to try to understand the rapid increase in the incidence of gout in recent decades.
Read Article
Nurse Led Gout Management Highly Effective
UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.
Read Article
It's the Genes, Not the Diet that Raises Urate
Researchers from New Zealand find that in contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population.
Read Article
Allopurinol Shown to be Renal Protective
Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.
Read Article
RheumNow Week in Review – I Wanna New Drug (9.28.18)
Dr. Jack Cush reviews the news from the past week on RheumNow.com, including news on inappropriate opioids, pre-clinical RA treatment, DMARDs in Gout, the decline of arthroscopy, and a pain in the mouth.
Read Article
Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid
The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC.
Read Article
RheumNow Week in Review – Gout and Hearing Loss, Huh? (9.14.18)
Dr. Jack Cush's weekly review of the news on RheumNow.com.
Read Article
RheumNow Week in Review – Medical School Advice (9.7.18)
Dr. Jack Cush reviews news and journal articles from the past week on RheumNow.com.
Read Article
ACR Releases State-by-State Rheumatic Disease Report Card
The American College of Rheumatology (ACR) today released the Rheumatic Disease Report Card: Raising the Grade on Rheumatology Care in America, a first-of-its-kind report that evaluates just how difficult it can be to live well with a rheumatic disease in the United States.
Read Article
Usual Allopurinol Doses Insufficient in CKD Patients
Uric acid (sUA) control may be a challenge in patients with chronic kidney disease (CKD). A cohort study shows that conventional dosing recommendations for allopurinol are unlikely to reach target serum sUA goals.
Read Article
